Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24457837 | 0.86 | LPL (0.41) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL18341043 | 0.86 | LPL (0.41) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL31518231 | 0.82 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL26814260 | 0.82 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL16760394 | 0.82 | POLB (0.42) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL20595129 | 0.81 | LPL (0.38) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL23057774 | 0.81 | LPL (0.40) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL16760393 | 0.80 | CSF1R (0.34) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL31518133 | 0.79 | LPL (0.39) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL12703333 | 0.79 | LPL (0.42) | LPLLIPGJAK2BTKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-2365970-B1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2365970-B1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2015079251-A1 | QUINAZOLINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079251-A1 | QUINAZOLINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | LPL 1508/4885LIPG 1629/4885JAK2 44/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | LPL 2085/4885LIPG 3333/4885JAK2 390/4885 |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | LPL 507/4885LIPG 1476/4885JAK2 29/4885 |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | LPL 507/4885LIPG 1476/4885JAK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.